Amal Gebara-Lamb

Ms. Amal Gebara-Lamb

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
KWKaren C. Wolff
Karen C. Wolff
LRLaura Riva
Laura Riva
AWAshley K. Woods
Ashley K. Woods
GGGennadii Grabovyi
Gennadii Grabovyi
ACArnab K. Chatterjee
Arnab K. Chatterjee
There remains a need to develop novel SARS-CoV-2 therapeutic options that improve upon existing therapies by an increased robustness of response, fewer safety liabilities, and global-ready accessibility. Functionally critical viral main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target due to its homology within the coronaviral family, and lack thereof toward human proteases. In this disclosure, we outline the advent of a novel SARS-CoV-2 3CLpro inhibitor, CMX990, bearing an unprecedented trifluoromethoxymethyl ketone warhead. Compared with the marketed drug nirmatrelvir (combination with ritonavir = Paxlovid), CMX990 has distinctly differentiated potency (∼5× more potent in primary cells) and human in vitro clearance (>4× better microsomal clearance and >10× better hepatocyte clearance), with good in vitro-to-in vivo correlation. Based on its compelling preclinical profile and projected once or twice a day dosing supporting unboosted oral therapy in humans, CMX990 advanced to a Phase 1 clinical trial as an oral drug candidate for SARS-CoV-2.

7 March 2025 in Viruses
Verified
Journal Article
Open access
PDF file
UBUlrich A.K. Betz
Ulrich A.K. Betz
RGRobert Garces
Robert Garces
NBNorbert Beier
Norbert Beier
SLSven Lindemann
Sven Lindemann
KWKaren C. Wolff
Karen C. Wolff
MEMagnus Evander
Magnus Evander
The pandemic threat from newly emerging viral diseases constitutes a major unsolved issue for global health. Antiviral therapy can play an important role in treating and preventing the spread of unprecedented viral infections. A repository of compounds exhibiting broad-spectrum antiviral activity against a series of different viral families would be an invaluable asset to be prepared for future pandemic threats. Utilizing an open innovation crowd-sourcing paradigm, we were able to identify a compound class of diphenylureas that exhibits in vitro antiviral activity against multiple viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), adenovirus, dengue virus, herpes, and influenza viruses. Compound 4 among the series exhibits strong activity against dengue virus, a growing global health problem with high medical need and no approved antiviral drug. The compounds are active against SARS-CoV-2 in a primary human stem cell-based mucociliary airway epithelium model and also active in vivo, as shown in a murine SARS-CoV-2 infection model. These results demonstrate the potential of the chemical class as antivirals on the one hand and the power of open innovation, crowd-sourcing, and repurposing on the other hand.

25 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
KWKaren C. Wolff
Karen C. Wolff
LRLaura Riva
Laura Riva
AWAshley K. Woods
Ashley K. Woods
GGGennadii Grabovyi
Gennadii Grabovyi
ACArnab K. Chatterjee
Arnab K. Chatterjee
There remains a need to develop novel SARS-CoV-2 therapeutic options that improve upon existing therapies by increased robustness of response, fewer safety liabilities, and global-ready accessibility. Functionally critical viral main protease (M pro , 3CL pro ) of SARS-CoV-2 is an attractive target due to its homology within the coronaviral family, and lack thereof towards human proteases. In this disclosure, we outline the advent of a novel SARS-CoV-2 3CL pro inhibitor, CMX990, bearing an unprecedented trifluoromethoxymethyl ketone warhead. Compared with the marketed drug nirmatrelvir (combination with ritonavir = Paxlovid TM ), CMX990 has distinctly differentiated potency (∼5x more potent in primary cells) and human in vitro clearance (>4x better microsomal clearance and >10x better hepatocyte clearance), with good in vitro - in vivo correlation. Based on its compelling preclinical profile and projected once or twice a day dosing supporting unboosted oral therapy in humans, CMX990 advanced to a Phase 1 clinical trial as an oral drug candidate for SARS-CoV-2.

26 July 2026 in Viruses
Verified
Journal Article
Open access
PDF file
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
KWKaren C. Wolff
Karen C. Wolff
FWFrank O Weiss
Frank O Weiss
SGSourav Ghorai
Sourav Ghorai
GGGennadii Grabovyi
Gennadii Grabovyi
ACArnab K. Chatterjee
Arnab K. Chatterjee
The use of covalent warheads targeting the catalytic cysteine has been a cornerstone in the coronavirus main protease (Mpro) inhibitor development. Various electrophilic motifs have been explored, including aldehydes, nitriles, ketoamides, and hydroxymethyl ketones (HMKs). Recent efforts have mostly centered around nitrile warheads, given the success of Nirmatrelvir in the clinic. However, it is essential to identify and develop alternative chemotypes with distinct chemical and pharmacological profiles to prepare for future pandemics. Among such alternatives, HMKs are of particular interest because they balance reduced intrinsic electrophilicity with an excellent selectivity profile. Nevertheless, early HMK-based compounds, such as the clinical-stage Mpro inhibitor PF-00835231, suffered from poor oral bioavailability and therefore required intravenous administration, with or without prodrug derivatization of the hydroxyl group. In this work, we describe our efforts to advance the HMK field by discovering mCMX110, a lead compound that exhibits superior potency, increased unbound exposure in vivo, and favorable oral bioavailability in preclinical studies.

10 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CSChandani Sen
Chandani Sen
TRTammy M. Rickabaugh
Tammy M. Rickabaugh
AJArjit Vijey Jeyachandran
Arjit Vijey Jeyachandran
CYConstance Yuen
Constance Yuen
MGMaisam Ghannam
Maisam Ghannam
BGBrigitte Gomperts
Brigitte Gomperts
Summary: Respiratory viruses (e.g. influenza, RSV, SARS etc.) attack the proximal airway and cause a wide spectrum of diseases for which we have limited therapies. To date, a few primary human stem cell-based models of the proximal airway have been reported for drug discovery but scaling them up to a higher throughput platform remains a significant challenge. Here we present a microscale, primary human stem cell-based proximal airway model of SARS-CoV-2 infection, which is amenable to moderate-to-high throughput drug screening. The model recapitulates the heterogeneity of infection seen among different patients and with different SARS-CoV-2 variants. We applied this model to screen 2100 compounds from targeted drug libraries using an image-based quantification method. While there were heterogeneous responses across variants for host factor targeting compounds, the direct acting antivirals showed a consistent response and we characterized a new antiviral drug that is effective against both the parental strain and the Omicron variant.

1 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NEN. G. R. Dayan Elshan
N. G. R. Dayan Elshan
KWKaren C. Wolff
Karen C. Wolff
LRLaura Riva
Laura Riva
MBMalina Bakowski
Malina Bakowski
SBSimeon Babarinde
Simeon Babarinde
ACArnab K. Chatterjee
Arnab K. Chatterjee
COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (M pro ) inhibitor bearing a unique trifluoromethoxymethyl ketone warhead. Here, we broadly evaluate its pan-coronavirus target engagement, antiviral breadth, and pharmacologic differentiation. Across a reporter panel of 24 M pro enzymes spanning alpha-, beta-, delta-, and gamma-coronaviruses, CMX990 retained robust potent activity, including against nirmatrelvir-resistant SARS-CoV-2 variants. In direct comparison, nirmatrelvir and ensitrelvir showed diminished potency against non-SARS-CoV-2 coronaviruses. Live-virus assays corroborated this breadth, with potent, selective activity against SARS-CoV-2, SARS-CoV-1, MERS-CoV, and additional human coronaviruses. Structural studies revealed a conserved covalent binding mode centered on the catalytic Cys of coronavirus M pro . In serial-passage studies, resistance emerged only after approximately twice as many serial passages under CMX990 selection as under nirmatrelvir selection, without selecting for the canonical nirmatrelvir-resistance substitution E166V. Extracellular washout experiments revealed superior persistence of antiviral activity relative to nirmatrelvir, consistent with durable target engagement. In a murine SARS-CoV-2 infection model, once-daily CMX990 protected against weight loss and reduced lung viral titers to near baseline levels. Collectively, these findings identify CMX990 as a structurally and functionally validated pan-coronavirus protease inhibitor supporting its potential as a pandemic-ready antiviral candidate.